BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36434517)

  • 1. Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
    Nyarubamba RF; Silumbwe A; Jacobs C; Maritim P; Mdoe P; Zulu JM
    BMC Infect Dis; 2022 Nov; 22(1):884. PubMed ID: 36434517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
    Robert M; Todd J; Ngowi BJ; Msuya SE; Ramadhani A; Sambu V; Jerry I; Mujuni MR; Mahande MJ; Ngocho JS; Maokola W
    BMC Infect Dis; 2020 Apr; 20(1):276. PubMed ID: 32276618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coverage of isoniazid preventive therapy among people living with HIV; A retrospective cohort study in Tanzania (2012-2016).
    Maokola W; Ngowi B; Lawson L; Robert M; Mahande M; Todd J; Msuya S
    Int J Infect Dis; 2021 Feb; 103():562-567. PubMed ID: 33276111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
    Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
    BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
    Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
    BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.
    Jacobson KB; Niccolai L; Mtungwa N; Moll AP; Shenoi SV
    AIDS Care; 2017 Jul; 29(7):936-942. PubMed ID: 28147705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-level managers' perspectives on implementing isoniazid preventive therapy for people living with HIV in Ugandan health districts: a qualitative study.
    Christian C; Kakande E; Nahurira V; Akatukwasa C; Atwine F; Bakanoma R; Itiakorit H; Owaraganise A; DiIeso W; Rast D; Kabami J; Peretz JJ; Shade SB; Kamya MR; Havlir DV; Chamie G; Camlin CS
    BMC Health Serv Res; 2024 Mar; 24(1):313. PubMed ID: 38454501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.
    Briggs MA; Emerson C; Modi S; Taylor NK; Date A
    J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3(Suppl 3):S297-305. PubMed ID: 25768869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid Preventive Therapy for Prevention of Tuberculosis among People Living with HIV in Ethiopia: A Systematic Review of Implementation and Impacts.
    Assefa DG; Zeleke ED; Bekele D; Ejigu DA; Molla W; Woldesenbet TT; Aynalem A; Abebe M; Mebratu A; Manyazewal T
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study.
    Wambiya EOA; Atela M; Eboreime E; Ibisomi L
    BMJ Open; 2018 Dec; 8(12):e024286. PubMed ID: 30573488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study.
    Ngugi SK; Muiruri P; Odero T; Gachuno O
    BMC Infect Dis; 2020 Apr; 20(1):294. PubMed ID: 32664847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania.
    Maokola WM; Ngowi BJ; Mahande MJ; Todd J; Robert M; Msuya SE
    PLoS One; 2021; 16(7):e0254082. PubMed ID: 34255776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
    Nyathi S; Dlodlo RA; Satyanarayana S; Takarinda KC; Tweya H; Hove S; Matambo R; Mandewo W; Nyathi K; Sibanda E; Harries AD
    PLoS One; 2019; 14(10):e0223076. PubMed ID: 31581271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania.
    Komba FF; Frumence G
    Pan Afr Med J; 2021; 38():197. PubMed ID: 33995803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania.
    Zhu J; Lyatuu G; Sudfeld CR; Kiravu A; Sando D; Machumi L; Minde J; Chisonjela F; Cohen T; Menzies NA
    Lancet Glob Health; 2022 Nov; 10(11):e1646-e1654. PubMed ID: 36240830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid preventive therapy use among adult people living with HIV in Zimbabwe.
    Takamiya M; Takarinda K; Balachandra S; Godfrey M; Radin E; Hakim A; Pearson ML; Choto R; Sandy C; Maphosa T; Rogers JH
    Int J STD AIDS; 2021 Oct; 32(11):1020-1027. PubMed ID: 33978529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
    Karanja M; Kingwara L; Owiti P; Kirui E; Ngari F; Kiplimo R; Maina M; Masini E; Onyango E; Ngugi C
    PLoS One; 2020; 15(12):e0234588. PubMed ID: 33264300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.
    Shayo GA; Moshiro C; Aboud S; Bakari M; Mugusi FM
    BMC Infect Dis; 2015 Aug; 15():368. PubMed ID: 26306511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.